Prostate stem cell compartments: Expression of the cell cycle inhibitor p27(Kip1) in normal, hyperplastic, and neoplastic cells

American Journal of Pathology

Volumn 153, Issue 3, 1998, Pages 911-919

  De Marzo, Angelo M ^a,b   Meeker, Alan K ^a   Epstein, Jonathan I ^a   Coffey, Donald S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STEM CELL;

EID: 0031683673     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65632-5     Document Type: Article

References (59)

1. Potten CS, Morris RJ: Epithelial stem cells in vivo. J Cell Science 1988, 10(Suppl):45-62
2. Potten CS, Loeffler M: Stem cells: attributes, cycles, spirals, pitfalls and uncertainties: lessons for and from the crypt. Development 1990, 110:1001-1020
3. Potten CS: Stem Cells, ed 1. London: Academic Press, 1997
4. Isaacs JT, Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate 1989, 2(Suppl):33-50
5. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994, 25:42-46
6. Bonkhoff H, Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996, 28:98-106
7. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988, 122:552-562
8. DeKlerk DP, Coffey DS: Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique: biomorphometrics. Invest Urol 1978, 16:240-245
9. McNeal JE: Regional morphology and pathology of the prostate. Am J Clin Pathol 1968, 49:347-357
10. McNeal JE: The zonal anatomy of the prostate. Prostate 1981, 2:35-49
11. McNeal JE: Normal histology of the prostate. Am J Surg Pathol 1988, 12:619-633
12. Brawer MK, Peehl DM, Stamey TA, Bostwick DG: Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985, 45:3663-3667
13. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski, JM, Lee C: Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 1990, 143:167-171
14. Bonkhoff H, Remberger K: Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol 1993, 422:35-38
15. Leav I, McNeal JE, Kwan PW, Komminoth P, Merk FB: Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 1996, 29:137-145
16. r 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res 1993, 53:4720-4726
17. Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pasternack GR: The novel nuclear phosphoprotein pp32 is highly expressed in intermediate and high grade prostate cancer. Prostate 1998, 34:231-237
18. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994, 91:11733-11737
19. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52:6940-6944
20. Epstein JI: PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 1993, 20:757-770
21. Sensibar JA, Alger B, Tseng A, Berg L, Lee C: Proteins of the rat prostate. III. Effect of testosterone on protein synthesis by the ventral prostate of castrated rats. J Urol 1990, 143:161-166
22. Sar M, Lubahn DB, French FS, Wilson EM: Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 1990, 127:3180-3186
23. Yang Y, Hao J, Liu X, Dalkin B, Nagle RB: Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. Am J Pathol 1997, 150: 693-704
24. Bonkhoff H, Stein U, Remberger K: The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994, 24:114-118
25. McNeal JE, Haillot O, Yemoto C: Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 1995, 27:258-268
26. Mao P, Angrist A: The fine structure of the basal cell of human prostate. Lab Invest 1966, 15:1768-1782
27. Lipschutz JH, Foster BA, Cunha GR: Differentiation of rat neonatal ventral prostates grown in a serum-free organ culture system. Prostate 1997, 32:35-42
28. Verhagen AP, Aalders TW, Ramaekers FC, Debruyne FM, Schalken JA: Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 1988, 13:25-38
29. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA: Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992, 52:6182-6187
30. Xue Y, Smedts F, Debruyne FM, de la Rosette JJ, Schalken JA: Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 1998, 34:292-301
31. McNeal JE, Bostwick DG: Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986, 17:64-71
32. Epstein JI: Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection. Semin Oncol 1994, 21:527-541
33. Roberts JM, Koff A, Polyak K, Firpo E, Collins S, Ohtsubo M, Massague J: Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol 1994, 59:31-38
34. Polyak K, Lee MH, Erdjumeni-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
35. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74
36. Coats S, Flanagan WM, Nourse J, Roberts JM: Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996, 272:877-880
37. Steeg PS, Abrams JS: Cancer prognostics: past, present and p27 [News: Comment]. Nat Med 1997, 3:152-154
38. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677
39. Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997, 3:2269-2274
40. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, Dekernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159:941-945
41. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998, 58:542-548
42. Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997, 88:625-629
43. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nat Med 1997, 3:593
44. 1a,b) invasive breast carcinomas. Cancer Res 1997, 57:1259-1263
45. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997, 3:227-230
46. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3:231-234
47. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385
48. Silberman MA, Partin AW, Veltri RW, Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1996, 79:772-779
49. Alessandrini A, Chiaur DS, Pagano M: Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997, 11:342-345
50. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3:231-234
51. van der Kwast TH, Tetu B: Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. Eur Urol 1996, 30:265-268
52. Bonkhoff H, Fixemer T, Remberger K: Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998, 34:251-258
53. Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol 1996, 20:86-93
54. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996, 155:213-219
55. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994, 79:487-496
56. Sanchez-Beato M, Saez AI, Martinez-Montero JC, Sol Mateo M, Sanchez-Verde L, Villuendas R, Troncone G, Piris MA: Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 1997, 151:151-160
57. Claus S, Wrenger M, Senge T, Schulze H: Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res 1993, 21:305-308
58. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995, 55:2910-2919
59. Polyak K, Hamilton SR, Vogelstein B, Kinzler KW: Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol 1996, 149:381-387